expected

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

American Picture House Corporate Update

Source Node:
Time Stamp: September 6, 2023 4:28 PM - Modified On: September 6, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, NY, Raleigh, NC, and Los Angeles, CA.  September 6, 2023 – American Picture House Corporation (OTC: APHP), an entertainment company with a focus on producing feature films, limited series, and entertainment enhancing technologies, today provided a corporate update for shareholders. Industry Strikes American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution. Update on Feature Films -

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

GMEX Group launches ZERO13 digital carbon credits aggregation ecosystem

Source Node:
Time Stamp: May 4, 2023 6:02 AM - Modified On: May 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Partners with Verdana Eco-Consortium, Alléo Energy and Pay DIRT London., May. 4, 2023 -- GMEX Group Limited (“GMEX”), a leader in digital business and technology solutions for capital, commodities and sustainability markets, announces the launch of ZERO13, a climate fintech. ZERO13 provides an automated AI and multi-blockchain driven aggregation ecosystem delivering trusted supply, digital issuance, trading, clearing and settlement for a broad range of carbon credits and related ESG real-world assets. ZERO13 digitally interconnects multiple stakeholders, including registries, banks, custodians, asset managers, corporates, buyers and sellers, markets, exchanges, climate tech

Broadhill Capital Announces its Capital Deployment Strategy for 2023.

Source Node:
Time Stamp: January 24, 2023 7:58 AM - Modified On: January 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Los Angeles CA January 24, 2023.  Broadhill Capital announced today that the firm will target to commit equity investment of USD $15 Billion across approximately 100-150 businesses.   “We expect to make non-control equity investments into businesses that have the potential to achieve 5-10x revenue growth with our capital commitment” stated investment committee member Francis König.  “We separate ourselves by our willingness to assist businesses in situations that often appear high risk to more conservative investors.”  Investment commitments are expected to range between USD $50 Million to $5 Billion per company,

Web3 and online entertainment – how will it change?

Source Node:
Time Stamp: March 23, 2022 2:32 PM - Modified On: February 26, 2024 - Published By:
Source Cluster:
Republished By Plato

The technology industry is buzzing with many new innovations. Metaverse, augmented and virtual reality and Web3 are just a few things that will change our everyday life and of course our perception of digital and technology. Web3 is a new version of the current internet network, which has been in use for decades. It is a network of shared source file based on blockchain technology that will revolutionize everything. Through it, you can enjoy an increasingly virtual and safer internet, where the sharing of your data is not decided by

Greenheart CBD Announces Quarter 1 Rebranding

Source Node:
Time Stamp: January 28, 2022 1:17 PM - Modified On: January 28, 2022 - Published By:
Source Cluster:
Republished By Plato

Greenheart CBD is welcoming a visual overhaul for their website and products as well as a new system to enable farmers across the globe to enter the CBD market, which was valued at $2.8 billion in 2020 and is expected to expand at a compound annual growth rate of 21.2% from 2021 to 2028. Greenheart tech The team at Greenheart has launched a B2B and B2C marketplace on the Google Play and Apple App store. The apps offer a permanent 40% discount on all products when utilizing the Greenheart CBD